SEER is an authoratitive source of information on cancer incidence and survival in the United States. SEER currently collects and publishes cancer incidence and survival data from population-based cancer registries covering approximately 28 percent of the U.S. population.
B lymphoblastic leukemia/lymphoma, not otherwise specified
A neoplasm of precursor cells (lymphoblasts) committed to the B-cell lineage, typically composed of small to medium sized blast cells. Most patients with B-ALL present with evidence of bone marrow failure, thrombocytopenia, anemia and neutropenia. Leukocyte number is decreased, lymphadenopathy, hepatomegaly and splenomegaly are frequent. Patients with B-LBL without leukemia are usually asymptomatic and most have limited stage disease. This is primarily a disease of children under 6 years of age
(This code is effective for cases diagnosed 2010 and later. For cases diagnosed prior to 2010 see codes: 9728/3 [lymphomas] or 9836/3 [leukemia].) Occurs mostly in children under six years of age. By definition, bone marrow is involved in all cases classified as B-ALL and peripheral blood is usually involved. Extramedullary involvement is frequent, with more common sites including the central nervous sytem, lymph nodes, spleen, liver and testis in males. The most frequent sites of involvement in B-LBL are the skin, soft tissue, bone and lymph nodes. Cytochemistry seldom contributes to the diagnosis of ALL.